Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma : Individual Patient Data Meta-analysis. / Mirian, Christian; Duun-Henriksen, Anne Katrine; Maier, Andrea; Pedersen, Maria Møller; Jensen, Lasse Rehné; Bashir, Asma; Graillon, Thomas; Hrachova, Maya; Bota, Daniela; van Essen, Martjin; Spanjol, Petar; Kreis, Christian; Law, Ian; Broholm, Helle; Poulsgaard, Lars; Fugleholm, Kåre; Ziebell, Morten; Munch, Tina; Walter, Martin A.; Mathiesen, Tiit.
I: Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Bind 62, Nr. 4, 2021, s. 507-513.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma
T2 - Individual Patient Data Meta-analysis
AU - Mirian, Christian
AU - Duun-Henriksen, Anne Katrine
AU - Maier, Andrea
AU - Pedersen, Maria Møller
AU - Jensen, Lasse Rehné
AU - Bashir, Asma
AU - Graillon, Thomas
AU - Hrachova, Maya
AU - Bota, Daniela
AU - van Essen, Martjin
AU - Spanjol, Petar
AU - Kreis, Christian
AU - Law, Ian
AU - Broholm, Helle
AU - Poulsgaard, Lars
AU - Fugleholm, Kåre
AU - Ziebell, Morten
AU - Munch, Tina
AU - Walter, Martin A.
AU - Mathiesen, Tiit
PY - 2021
Y1 - 2021
N2 - Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas. Methods: We performed an individual patient data meta-analysis, including all published data on meningioma patients treated with SSTR-targeted PRRT. The main outcomes were toxicity, response to treatment, progression-free survival (PFS), and overall survival (OS). We applied the Kaplan-Meier method to estimate survival probabilities and report incidence rates per 100 person-years. We applied Cox proportional hazards models to determine the effect of covariates. Results: We screened 537 papers and identified 6 eligible cohort studies. We included a total of 111 patients who had treatment-refractory meningioma and received SSTR-targeted PRRT. Disease control was achieved in 63% of patients. The 6-mo PFS rates were 94%, 48%, and 0% for World Health Organization grades I, II, and III, respectively. The risk of disease progression decreased by 13% per 1,000-MBq increase in the total applied activity. The 1-y OS rates were 88%, 71%, and 52% for World Health Organization grades I, II, and III, respectively. The risk of death decreased by 17% per 1,000-MBq increase in the total applied activity. The main side effects comprised transient hematotoxicity, such as anemia in 22% of patients, leukopenia in 13%, lymphocytopenia in 24%, and thrombocytopenia in 17%. Conclusion: To our knowledge, this individual patient data meta-analysis represents the most comprehensive analysis of the benefits of and adverse events associated with SSTR-targeted PRRT for treatment-refractory meningioma. The treatment was well tolerated, achieved disease control in most cases, and showed promising results regarding PFS and OS.
AB - Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas. Methods: We performed an individual patient data meta-analysis, including all published data on meningioma patients treated with SSTR-targeted PRRT. The main outcomes were toxicity, response to treatment, progression-free survival (PFS), and overall survival (OS). We applied the Kaplan-Meier method to estimate survival probabilities and report incidence rates per 100 person-years. We applied Cox proportional hazards models to determine the effect of covariates. Results: We screened 537 papers and identified 6 eligible cohort studies. We included a total of 111 patients who had treatment-refractory meningioma and received SSTR-targeted PRRT. Disease control was achieved in 63% of patients. The 6-mo PFS rates were 94%, 48%, and 0% for World Health Organization grades I, II, and III, respectively. The risk of disease progression decreased by 13% per 1,000-MBq increase in the total applied activity. The 1-y OS rates were 88%, 71%, and 52% for World Health Organization grades I, II, and III, respectively. The risk of death decreased by 17% per 1,000-MBq increase in the total applied activity. The main side effects comprised transient hematotoxicity, such as anemia in 22% of patients, leukopenia in 13%, lymphocytopenia in 24%, and thrombocytopenia in 17%. Conclusion: To our knowledge, this individual patient data meta-analysis represents the most comprehensive analysis of the benefits of and adverse events associated with SSTR-targeted PRRT for treatment-refractory meningioma. The treatment was well tolerated, achieved disease control in most cases, and showed promising results regarding PFS and OS.
KW - peptide receptor radionuclide therapy
KW - progressive meningioma
KW - somatostatin receptor
KW - treatment-refractory meningioma
U2 - 10.2967/jnumed.120.249607
DO - 10.2967/jnumed.120.249607
M3 - Journal article
C2 - 32859705
AN - SCOPUS:85103683038
VL - 62
SP - 507
EP - 513
JO - The Journal of Nuclear Medicine
JF - The Journal of Nuclear Medicine
SN - 0161-5505
IS - 4
ER -
ID: 259882426